Non-Muscle-Invasive Bladder Cancer (NMIBC) refers to early-stage bladder cancers that are confined to the inner lining (urothelium) or submucosa of the bladder without invading the muscle layer (detrusor muscle). It accounts for ~75% of all bladder cancer cases at diagnosis.
Classification & Risk Stratification
NMIBC is categorized based on tumor stage (TNM system) and grade (aggressiveness):
1. Stages (Tumor, T Category)
- Ta: Papillary tumor confined to the urothelium (most common, ~70%).
- T1: Tumor invades the lamina propria (submucosa) but not the muscle.
- CIS (Carcinoma in situ): Flat, high-grade tumor confined to the urothelium (“pre-invasive” but aggressive).
2. Grades (WHO 1973/2004)
- Low-grade (LG): Slow-growing, less aggressive.
- High-grade (HG): More likely to progress to muscle invasion.
3. Risk Groups (EAU/AUA Guidelines)
| Risk Category | Features | Recurrence/Progression Risk |
|---|---|---|
| Low-risk | Single, small (<3 cm), low-grade Ta | Low recurrence (~15–30%), minimal progression risk |
| Intermediate-risk | Multiple/recurrent Ta or low-grade T1 | Moderate recurrence (~30–50%), low progression |
| High-risk | High-grade T1, CIS, large/multifocal tumors | High recurrence (~50–70%), significant progression risk (up to 50%) |
Treatment Approaches
Treatment depends on risk stratification:
1. Surgical (First Step)
- TURBT (Transurethral Resection of Bladder Tumor): Primary diagnostic & therapeutic procedure.
2. Adjuvant (Post-TURBT) Therapies
- Low-risk: Single-dose intravesical chemotherapy (e.g., Mitomycin C, Gemcitabine) immediately post-TURBT.
- Intermediate-risk: Induction + maintenance chemo (MMC) or BCG (if higher-risk features).
- High-risk: BCG immunotherapy (gold standard) + maintenance (3-year protocol).
- BCG-unresponsive: Clinical trials, chemo (Gem/Doce), or radical cystectomy.
3. Surveillance (Follow-Up)
- Cystoscopy + urine cytology every 3–12 months (based on risk).
- High-risk patients: Lifelong monitoring due to progression risk.
Prognosis
- Recurrence: 30–80% (depends on risk group).
- Progression to muscle-invasive disease (MIBC):
- Low-risk: <5%
- High-risk: Up to 50% (especially with T1+CIS).
Key Challenges
- BCG shortages → Alternative chemo (Gemcitabine/MMC).
- BCG failure → Emerging options (PD-1 inhibitors, combination therapies).